Literature DB >> 16050909

Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.

M Kiupel1, J D Webster, R A Miller, J B Kaneene.   

Abstract

The goal of this study was to determine the significance of tumour depth, tumour location and multiple synchronous tumour masses for the prognostic evaluation of canine cutaneous mast cell tumours (MCTs). The study population consisted of 100 formalin-fixed, paraffin-embedded cutaneous MCTs that had been surgically removed from 100 dogs and submitted to the Diagnostic Center of Population and Animal Health at Michigan State University between 1998 and 2001. None of the dogs had received chemotherapy or radiation therapy. For each case the following data were obtained from the referring veterinarians: sex, breed, weight, age at diagnosis, diagnostics performed, adjunct medications given at the time of surgery, tumour location, number of tumour masses, tumour recurrence (development of MCTs at the surgical site), development of additional MCTs at distant sites (outside the surgical margins), tumour duration before removal, survival time and cause of death, if applicable. Tumour depth was determined through microscopic evaluation of 5 microm sections stained with haematoxylin and eosin. Based on univariable and multivariable survival analysis, dogs with multiple synchronous cutaneous MCTs at the time of diagnosis have a worse prognosis compared with dogs with single tumours. Additional treatment beyond surgical excision alone should be considered for these animals. Older dogs and Boxers with cutaneous MCTs were at higher risk to develop additional MCTs at distant sites (outside the surgical margins), and older and male dogs with cutaneous MCTs had significantly shorter survival times. Univariable analysis also determined that dogs with cutaneous MCTs located on the head and neck had an increased risk of additional MCT development at distant sites and that sterilized dogs with cutaneous MCTs had shorter survival times. However, these findings were not confirmed by multivariable analysis. Tumour depth was of no prognostic significance for dogs with cutaneous MCTs.

Entities:  

Mesh:

Year:  2005        PMID: 16050909     DOI: 10.1111/j.1439-0442.2005.00726.x

Source DB:  PubMed          Journal:  J Vet Med A Physiol Pathol Clin Med        ISSN: 0931-184X


  15 in total

Review 1.  DCE-MRI: a review and applications in veterinary oncology.

Authors:  M Keara Boss; N Muradyan; D E Thrall
Journal:  Vet Comp Oncol       Date:  2011-12-08       Impact factor: 2.613

2.  Canine mast cell tumours part I: Clinical and survival outcomes.

Authors:  Vanessa S Tamlin; Cynthia D K Bottema; Lucy Woolford; Elizabeth C Dobson; Allan E Kessell; Anne E Peaston
Journal:  Vet Med Sci       Date:  2022-05-03

3.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

4.  Prevalence and risk factors for mast cell tumours in dogs in England.

Authors:  Stephanie Jw Shoop; Stephanie Marlow; David B Church; Kate English; Paul D McGreevy; Anneliese J Stell; Peter C Thomson; Dan G O'Neill; David C Brodbelt
Journal:  Canine Genet Epidemiol       Date:  2015-01-26

5.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

6.  Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification.

Authors:  Anna Śmiech; Brygida Ślaska; Wojciech Łopuszyński; Agnieszka Jasik; Diana Bochyńska; Roman Dąbrowski
Journal:  Acta Vet Scand       Date:  2018-11-03       Impact factor: 1.695

7.  Mast cell tumours and other skin neoplasia in Danish dogs--data from the Danish Veterinary Cancer Registry.

Authors:  Louise B Brønden; Thomas Eriksen; Annemarie T Kristensen
Journal:  Acta Vet Scand       Date:  2010-01-22       Impact factor: 1.695

8.  Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.

Authors:  Joshua D Webster; Vilma Yuzbasiyan-Gurkan; Douglas H Thamm; Elizabeth Hamilton; Matti Kiupel
Journal:  BMC Vet Res       Date:  2008-08-13       Impact factor: 2.741

9.  CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers.

Authors:  Rui M Gil da Costa; Eduarda Matos; Alexandra Rema; Célia Lopes; Maria A Pires; Fátima Gärtner
Journal:  BMC Vet Res       Date:  2007-08-21       Impact factor: 2.741

10.  Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline.

Authors:  L Marconato; E Zorzan; M Giantin; S Di Palma; S Cancedda; M Dacasto
Journal:  J Vet Intern Med       Date:  2013-12-26       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.